High affinity nerve growth factor receptor (TRKA) (TRKA)

The High affinity nerve growth factor receptor (TRKA), encoded by the NTRK1 gene, is a transmembrane protein that serves as a key mediator of neuronal growth and survival (UniProt P04629). It is primarily expressed in the nervous system, where it serves as the high-affinity receptor for nerve growth factor (NGF) (PubMed: 15367582). Upon ligand binding, TRKA undergoes dimerization and autophosphorylation, activating downstream signaling pathways such as PI3K/Akt and MAPK/ERK that are essential for neuronal survival and differentiation (PubMed: 15367582). In the context of human disease, chromosomal rearrangements involving the NTRK1 gene lead to the production of oncogenic fusion proteins with constitutive kinase activity, driving various solid tumors (PubMed: 29445119). These fusions are found in a wide range of cancers, including secretory breast carcinoma, infantile fibrosarcoma, and lung adenocarcinoma (PubMed: 30635439). Consequently, TRKA has become a major therapeutic target for "tumor-agnostic" precision medicines like larotrectinib and entrectinib (FDA.gov). Beyond oncology, TRKA signaling is a key component of the pain pathway, and its dysfunction is linked to congenital insensitivity to pain with anhidrosis (CIPA) (PubMed: 8644709). Therapeutic strategies targeting TRKA also include the development of inhibitors for chronic pain management, though neurotoxicity remains a significant clinical challenge (PubMed: 25109398).

Other names

NTRK1Tropomyosin receptor kinase ATRKp140-TrkAMTCTRK1

Small molecule inhibition of the tropomyosin receptor kinase (TRK) family (TRKA, TRKB, and TRKC) by competing for the ATP-binding site, thereby blocking downstream oncogenic signaling (PubMed: 29445119).